{"entity":{"id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","summary":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT05528133 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 86 participants, started 2023-01-25 and due to reach its primary completion in 2028-05. Interventions recorded: Genomically Guided Radiation Therapy; Genomically Guided Radiation Therapy. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Confirmation of Triple Negative (TN) breast cancer by tissue biopsy\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05528133","url":"https://clinicaltrials.gov/study/NCT05528133"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05528133","phase":"2","setting":"Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","enrolled":86,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05528133/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}